The Surviving Sepsis Campaign: A History and a Perspective

被引:34
作者
Marshall, John C. [1 ,2 ,3 ]
Dellinger, R. Phillip [4 ,5 ]
Levy, Mitchell [6 ]
机构
[1] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Toronto, ON M5B 1W8, Canada
[3] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
[4] Univ Med & Dent New Jersey, Dept Med, Div Crit Care Med, Camden, NJ USA
[5] Cooper Univ Hosp, Camden, NJ USA
[6] Brown Univ, Rhode Isl Hosp, Warren Alpert Sch Med, Dept Pulm Crit Care & Sleep Med, Providence, RI 02903 USA
关键词
ACTIVATED PROTEIN-C; SEPTIC SHOCK; INTERNATIONAL GUIDELINES; DIRECTED THERAPY; CARE; TRIAL; MANAGEMENT; HYDROCORTISONE; MULTICENTER; MORTALITY;
D O I
10.1089/sur.2010.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The Surviving Sepsis Campaign (SSC) was launched in 2002 as a collaborative initiative of the European Society of Intensive Care Medicine (ESICM), the International Sepsis Forum (ISF), and the Society of Critical Care Medicine (SCCM). Its objective was, through the development and promulgation of evidence-based guidelines that facilitated the application of knowledge derived from clinical trials to bedside practice, to effect a 25% reduction in the relative risk of death from severe sepsis and septic shock. Methods: The evolution and content of the SSC is summarized and the scientific basis of the conclusions is reviewed from the literature. Results: The SSC developed evidence-based management guidelines and undertook a broad educational program to implement them by integrating their recommendations into resuscitation and management bundles. The process engaged practitioners in North America, Europe, and South America and was supported by professional societies around the world. It also engendered controversy based on accusations of undue industry influence and some dissatisfaction among individuals who were antagonistic toward protocolization of care. By its conclusion, more than 22,000 patients with sepsis had been entered in the SSC database, and analysis of the results showed that participation in the SSC was associated with a 5.4% absolute survival benefit. Conclusions: The SSC has impacted the care of septic patients and catalyzed changes that are likely to persist and evolve.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 44 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [3] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [4] Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Antman, EM
    Morrow, DA
    McCabe, CH
    Murphy, SA
    Ruda, M
    Sadowski, Z
    Budaj, A
    López-Sendón, JL
    Guneri, S
    Jiang, F
    White, HD
    Fox, KAA
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) : 1477 - 1488
  • [5] Barie Philip S, 2006, Surg Infect (Larchmt), V7, P485, DOI 10.1089/sur.2006.7.485
  • [6] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [7] The 100 000 Lives Campaign - Setting a goal and a deadline for improving health care quality
    Berwick, DM
    Calkins, DR
    McCannon, CJ
    Hackbarth, AD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (03): : 324 - 327
  • [8] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [9] Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.
    Brower, RG
    Matthay, MA
    Morris, A
    Schoenfeld, D
    Thompson, BT
    Wheeler, A
    Wiedemann, HP
    Arroliga, AC
    Fisher, CJ
    Komara, JJ
    Perez-Trepichio, P
    Parsons, PE
    Wolkin, R
    Welsh, C
    Fulkerson, WJ
    MacIntyre, N
    Mallatratt, L
    Sebastian, M
    McConnell, R
    Wilcox, C
    Govert, J
    Thompson, D
    Clemmer, T
    Davis, R
    Orme, J
    Weaver, L
    Grissom, C
    Eskelson, M
    Young, M
    Gooder, V
    McBride, K
    Lawton, C
    d'Hulst, J
    Peerless, JR
    Smith, C
    Brownlee, J
    Pluss, W
    Kallet, R
    Luce, JM
    Gottlieb, J
    Elmer, M
    Girod, A
    Park, P
    Daniel, B
    Gropper, M
    Abraham, E
    Piedalue, F
    Glodowski, J
    Lockrem, J
    McIntyre, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) : 1301 - 1308
  • [10] CLINICAL RECOMMENDATIONS USING LEVELS OF EVIDENCE FOR ANTITHROMBOTIC AGENTS
    COOK, DJ
    GUYATT, GH
    LAUPACIS, A
    SACKETT, DL
    GOLDBERG, RJ
    [J]. CHEST, 1995, 108 (04) : S227 - S230